ACT Genomics
Taiwan - TaipeiBiotechnology
Focus: ACT Genomics is a Taiwan-based cancer genomic profiling company founded in 2014, focused on oncology precision diagnostics and biomarker-driven research. The company operates as a publicly listed biotech firm specializing in sequence analysis and companion diagnostics.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3
Should You Work at ACT Genomics?
AI assessmentACT Genomics is a specialized diagnostic-focused biotech with modest hiring velocity; suitable for candidates seeking precision oncology expertise but carrying execution risk given limited pipeline and opaque financials.
Why Work Here
- Precision oncology and genomic profiling represent high-growth diagnostic segments with expanding clinical adoption and reimbursement tailwinds.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
non intervention
Sequence AnalysisClinical Trials (1)
NCT03719222Analysis of Tumor Mutations and Tumor Microenvironment Using Archival Paraffin-embedded Tumor Specimens
N/AHelp build intelligence for ACT Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.